Literature DB >> 8720616

Antibodies to glutamic acid decarboxylase induced by interferon-alpha therapy for chronic viral hepatitis.

A Imagawa, N Itoh, T Hanafusa, M Waguri, M Kuwajima, Y Matsuzawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8720616     DOI： 10.1007/BF00400426

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  7 in total

1.  Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis.

Authors:  P Fabris; C Betterle; A Floreani; N A Greggio; F de Lazzari; R Naccarato; M Chiaramonte
Journal:  Lancet       Date:  1992-08-29       Impact factor: 79.321

2.  Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa.

Authors:  M Lisker-Melman; A M Di Bisceglie; S J Usala; B Weintraub; L M Murray; J H Hoofnagle
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

3.  Interferon expression in the pancreases of patients with type I diabetes.

Authors:  X Huang; J Yuang; A Goddard; A Foulis; R F James; A Lernmark; R Pujol-Borrell; A Rabinovitch; N Somoza; T A Stewart
Journal:  Diabetes       Date:  1995-06       Impact factor: 9.461

4.  Two types of autoantibodies to adrenal medullary cells in type 1 (insulin-dependent) diabetic patients: prevalence, properties and implications.

Authors:  N Itoh; T Hanafusa; H Katsura; K Yamamoto; A Takeda; A Kurahashi; T Nabika; A Miyazaki; J Miyagawa; N Kono
Journal:  J Autoimmun       Date:  1991-10       Impact factor: 7.094

5.  Occurrence of IDDM during interferon therapy for chronic viral hepatitis.

Authors:  M Waguri; T Hanafusa; N Itoh; A Imagawa; J Miyagawa; S Kawata; N Kono; M Kuwajima; Y Matsuzawa
Journal:  Diabetes Res Clin Pract       Date:  1994-02       Impact factor: 5.602

6.  Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus.

Authors:  A K Foulis; M A Farquharson; A Meager
Journal:  Lancet       Date:  1987-12-19       Impact factor: 79.321

7.  Evaluation of islet-specific autoantibodies in Japanese patients with insulin-dependent diabetes mellitus: a comparison between autoantibodies to glutamic acid decarboxylase, autoantibodies to 64 kDa islet cell protein and islet cell antibodies.

Authors:  E Kawasaki; H Takino; M Yano; S Uotani; K Matsumoto; Y Yamaguchi; S Akazawa; S Nagataki
Journal:  J Autoimmun       Date:  1994-12       Impact factor: 7.094
  7 in total
  4 in total

Review 1.  The role of interleukin-1 in the pathogenesis of IDDM.

Authors:  T Mandrup-Poulsen
Journal:  Diabetologia       Date:  1996-09       Impact factor: 10.122

2.  Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C.

Authors:  B Wesche; E Jaeckel; C Trautwein; H Wedemeyer; A Falorni; H Frank; A von zur Mühlen; M P Manns; G Brabant
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

3.  Expression of endocrine autoantibodies in chronic hepatitis C, before and after interferon-alpha therapy.

Authors:  G Murdolo; D Francisci; F Forini; F Baldelli; G Angeletti; G Stagni; F Santeusanio; F Calcinaro; A Falorni
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

4.  Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.

Authors:  Laura M Stinton; Robert P Myers; Carla S Coffin; Marvin J Fritzler
Journal:  BMC Gastroenterol       Date:  2013-03-19       Impact factor: 3.067
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.